Pozitron-emission tomografiya (PET) — tibbiyotda yangi tashxis imkoniyatlari va uning fizik asoslari

Authors

  • Zokirov Abdusamad Soyibjonovich Toshkent davlat tibbiyot universiteti "Tibbiy radiologiya" kafedrasi talabasi T/r Toshkent davlat tibbiyot universiteti talabasi Author
  • Raxmonova Gulbahor Ergashevna Toshkent davlat tibbiyot universiteti 1-son tibbiyot radiologiyasi kafedrasi professori, tibbiyot fanlari doktori Author
  • Bozorboyeva Fotima Toshkent davlat tibbiyot universiteti, Tibbiy radiologiya kafedrasi magistranti T/r Toshkent davlat tibbiyot universiteti talabasi Author

DOI:

https://doi.org/10.5281/zenodo.20115073

Keywords:

(18) F-FDG; PET/KT; PET/MRT; pozitron emission tomografiya, annigilyatsiya

Abstract

 Pozitron-emission tomografiya (PET) molekulyar vizualizatsiya sohasidagi muhim usul bo‘lib, u bosqichma-bosqich bemor parvarishiga ta’sir ko‘rsatib, xavfsiz, tez va ishonchli usullarni taqdim etadi. Bu esa invaziv muolajalarga ehtiyojni kamaytirish hamda ayrim eskirgan usullarni amaliyotdan chiqarishga yordam beradi. Bundan tashqari, PET kasallik patofiziologiyasida ishtirok etuvchi molekulyar mexanizmlar bilan maqsadli davolash usullari o‘rtasidagi muhim bog‘liqlikni ta’minlaydi. So‘nggi yillarda PET-tasvirlash texnologiyasi dori vositalarini yetkazib berish sohasida ham keng qo‘llanilmoqda. Zamonaviy tadqiqotlar maksimal terapevtik samaradorlikka erishish, aniq maqsadli yo‘naltirish, dozani to‘g‘ri yetkazish va zaharlilikni kamaytirishga qaratilgan yangi tizimlarni ishlab chiqishga yo‘naltirilgan. PET-tasvirlash va nazorat ostida dori yetkazib berish texnologiyalarini birlashtirishga bo‘lgan qiziqish tobora ortib bormoqda. PET asosidagi dori yetkazib berish tizimlari bemorlarni davolash jarayonini tubdan o‘zgartirish salohiyatiga ega. Hozirgacha e’lon qilingan klinik oldi tadqiqot natijalari juda istiqbolli bo‘lib, bunday strategiyalar saraton kasalligini tashxislash va davolash samaradorligini oshirishi hamda bemorlarning hayot sifatini yaxshilashi mumkinligini ko‘rsatmoqda.

References

1.Willemse JRJ, et al. FDG PET/CT in cancer of unknown primary: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2024;51(5):1201–1215.

2.Groheux D, et al. Role of 18F-FDG PET/CT in metastatic breast cancer: recent advances. Eur J Nucl Med Mol Imaging. 2024;51(3):845–859.

3.Molnar O, et al. Modern radiopharmaceuticals in PET/CT imaging: a comprehensive review. Diagnostics (Basel). 2024;14(2):210.

4.Sharma A, et al. Clinical applications of PET/CT in head and neck cancers. Cancers (Basel). 2024;16(4):785.

5.Caresia AP, et al. FAPI PET/CT in oncology: emerging clinical applications. J Nucl Med. 2024;65(6):987–995.

6.Zajkowska K, et al. FDG PET/CT in lymphoma: updated clinical role. Diagnostics (Basel). 2024;14(6):670.

7.van der Broeck LCA, et al. FDG PET/CT in infection and inflammation imaging. Eur J Nucl Med Mol Imaging. 2024;51(7):1800–1814.

8.Ebner R, et al. Advances in PET/CT imaging for cancer staging and restaging. Eur J Radiol. 2025;172:111234.

9.Han EJ, et al. Clinical utility of FDG PET/CT in oncology patients: recent developments. Diagnostics (Basel). 2025;15(1):55.

10.Boellaard R, et al. Updated EANM guidelines for FDG PET/CT imaging. Eur J Nucl Med Mol Imaging. 2025;52(2):300–320.

11.Kapsoritakis N, et al. PET/CT in pulmonary nodules: diagnostic performance and clinical impact. Respir Med. 2025;210:107145.

12.Safarian A, et al. Radiomics and artificial intelligence in PET imaging of lung cancer. Eur J Nucl Med Mol Imaging. 2025;52(4):950–965.

13.Mladin R, et al. PET/CT for monitoring immunotherapy response in non-small cell lung cancer. Diagnostics (Basel). 2025;15(3):320.

14.Pu Y, et al. Diagnostic value of PET/CT in pulmonary lymphoma. Front Oncol. 2025;15:1287456.

Downloads

Published

2026-05-11